Health Education England, UK.
The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
Ann R Coll Surg Engl. 2022 Sep;104(8):611-617. doi: 10.1308/rcsann.2022.0045. Epub 2022 May 31.
Appropriate patient selection within the context of a multidisciplinary team (MDT) is key to good clinical outcomes. The current evidence base for factors that guide the decision-making process in locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC) is limited to anatomical factors.
A registry-based, prospective cohort study was undertaken of patients referred to our specialist MDT between 2015 and 2019. Data were collected on patients and disease characteristics including performance status, Charlson Comorbidity Index, the English Index of Multiple Deprivation quintiles and MDT treatment decision. Curative treatment was defined as neoadjuvant treatment and surgical resection that would achieve a R0 resection, and/or complete treatment of distant metastatic disease. Palliative treatment was defined as non-surgical treatment.
In total, 325 patients were identified; 72.7% of patients with LARC and 63.6% of patients with LRRC were offered treatment with curative intent (= 0.08). Patients with poor performance status (PS > 2; < 0.001), severe comorbidity (< 0.001), socio-economic deprivation (= 0.004), a positive predictive circumferential resection margin (= 0.005) and metastatic disease (< 0.001) were associated with palliative treatment. Overall survival in the curative cohort was 49 months (95% confidence interval [CI] 32.4-65.5) compared with 12 months (95% CI 9.1-14.9) in the palliative cohort (< 0.001). The presence of metastatic disease was identified as a prognostic factor for patients undergoing curative treatment (= 0.05). The only prognostic factor identified in patients treated palliatively was performance status (< 0.001).
Our study identifies a number of preoperative, prognostic factors that affect MDT decision-making and overall survival.
在多学科团队(MDT)的背景下,适当的患者选择是获得良好临床结果的关键。目前,指导局部进展期直肠癌(LARC)和局部复发性直肠癌(LRRC)决策过程的循证医学证据仅限于解剖因素。
本研究为 2015 年至 2019 年期间向我们的专家 MDT 转诊的患者进行了基于登记的前瞻性队列研究。收集了患者和疾病特征的数据,包括身体状况、Charlson 合并症指数、英国多重剥夺五分位数指数和 MDT 治疗决策。根治性治疗定义为新辅助治疗和手术切除可实现 R0 切除和/或完全治疗远处转移疾病。姑息性治疗定义为非手术治疗。
共确定了 325 名患者;72.7%的 LARC 患者和 63.6%的 LRRC 患者接受了有治愈意图的治疗(=0.08)。身体状况较差(PS>2;<0.001)、严重合并症(<0.001)、社会经济剥夺(=0.004)、阳性预测环周切缘(=0.005)和转移性疾病(<0.001)的患者与姑息性治疗相关。在根治性队列中,总生存时间为 49 个月(95%置信区间[CI]32.4-65.5),而姑息性队列中为 12 个月(95%CI9.1-14.9)(<0.001)。转移性疾病的存在被确定为接受根治性治疗的患者的预后因素(=0.05)。在姑息性治疗的患者中,唯一确定的预后因素是身体状况(<0.001)。
本研究确定了一些术前预后因素,这些因素影响 MDT 决策和总体生存。